No CrossRef data available.
Article contents
Insomnia and parasomnia induced by validated smoking cessation pharmacotherapies and electronic cigarettes: a network meta-analysis
Published online by Cambridge University Press: 04 March 2024
Abstract
We aim to assess the relationship between validated smoking cessation pharmacotherapies and electronic cigarettes (e-cigarettes) and insomnia and parasomnia using a systematic review and a network meta-analysis. A systematic search was performed until August 2022 in the following databases: PUBMED, COCHRANE, CLINICALTRIAL. Randomized controlled studies against placebo or validated therapeutic smoking cessation methods and e-cigarettes in adult smokers without unstable or psychiatric comorbidity were included. The primary outcome was the presence of “insomnia” and “parasomnia.” A total of 1261 studies were selected. Thirty-seven studies were included in the quantitative analysis (34 for insomnia and 23 for parasomnia). The reported interventions were varenicline (23 studies), nicotine replacement therapy (NRT, 10 studies), bupropion (15 studies). No studies on e-cigarettes were included. Bayesian analyses found that insomnia and parasomnia are more frequent with smoking cessation therapies than placebo except for bupropion. Insomnia was less frequent with nicotine substitutes but more frequent with bupropion than the over pharmacotherapies. Parasomnia are less frequent with bupropion but more frequent with varenicline than the over pharmacotherapies. Validated smoking cessation pharmacotherapies can induce sleep disturbances with different degrees of frequency. Our network meta-analysis shows a more favorable profile of nicotine substitutes for insomnia and bupropion for parasomnia. It seems essential to systematize the assessment of sleep disturbances in the initiation of smoking cessation treatment. This could help professionals to personalize the choice of treatment according to sleep parameters of each patient. Considering co-addictions, broadening the populations studied and standardizing the measurement are additional avenues for future research.
Keywords
- Type
- Review
- Information
- Copyright
- © The Author(s), 2024. Published by Cambridge University Press
References
Tobacco. World Health Organization. [Internet]. https://www.who.int/fr/news-room/fact-sheets/detail/tobacco.Google Scholar
World Health Organization, Management of Substance Abuse Team, World Health Organization. Global Status Report on Alcohol and Health; 2018. http://www.who.int/substance_abuse/publications/global_alcohol_report/en/.Google Scholar
Degenhardt, L, Charlson, F, Ferrari, A, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987–1012.CrossRefGoogle Scholar
Perriot, J, Underner, M, Peiffer, G. Smoking cessation in “difficult smokers”. Revue des maladies respiratoires. 2012;29(4):448–461.CrossRefGoogle Scholar
Vijayaraghavan, M, Schroeder, SA, Kushel, M. The effectiveness of tobacco control policies on vulnerable populations in the USA: a review. Postgrad Med J. 2016;92(1093):670–676.CrossRefGoogle ScholarPubMed
Jamal, A, Phillips, E, Gentzke, AS, et al. Current cigarette smoking among adults — United States, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(2):53–59.CrossRefGoogle Scholar
Piper, ME, Cook, JW, Schlam, TR, et al. Gender, race, and education differences in abstinence rates among participants in two randomized smoking cessation trials. Nicotine Tob Res. 2010;12(6):647–657.CrossRefGoogle ScholarPubMed
Cahill, K, Stevens, S, Lancaster, T. Pharmacological treatments for smoking cessation. JAMA. 2014;311(2):193–194. doi:10.1001/jama.2013.283787.CrossRefGoogle ScholarPubMed
Hartmann‐Boyce, J, Chepkin, SC, Ye, W, Bullen, C, Lancaster, T. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018;5(5):CD000146. doi:10.1002/14651858.CD000146.pub5.Google ScholarPubMed
Cahill, K, Lindson‐Hawley, N, Thomas, KH, Fanshawe, TR, Lancaster, T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2016;2016(5):CD006103. doi:10.1002/14651858.CD006103.pub7.Google ScholarPubMed
Marlatt, GA, Donovan, DM, eds. Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors. 2nd ed. New York: Guilford Press; 2005.Google Scholar
Yeomans, K, Payne, KA, Marton, JP, et al. Smoking, smoking cessation and smoking relapse patterns: a web-based survey of current and former smokers in the US. Int J Clin Pract. 2011;65(10):1043–1054.CrossRefGoogle ScholarPubMed
Farsalinos, KE, Poulas, K, Voudris, V, Le Houezec, J. Electronic cigarette use in the European Union: analysis of a representative sample of 27 460 Europeans from 28 countries. Addiction. 2016; 111(11):2032–2040.CrossRefGoogle Scholar
Levy, DT, Borland, R, Lindblom, EN, et al. Potential deaths averted in USA by replacing cigarettes with e-cigarettes. Tob Control. 2018;27(1):18–25.CrossRefGoogle ScholarPubMed
Hartmann-Boyce, J, McRobbie, H, Butler, AR, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. 2021;4(4):CD010216.Google ScholarPubMed
Benowitz, NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol. 2009;49:57–71.CrossRefGoogle Scholar
Gibson, M, Munafò, MR, Taylor, AE, Treur, JL. Evidence for genetic correlations and bidirectional, causal effects between smoking and sleep behaviors. Nicotine Tob Res. 2018;21(6):731–738.CrossRefGoogle Scholar
Zhang, L, Samet, J, Caffo, B, Punjabi, NM. Cigarette smoking and nocturnal sleep architecture. Am J Epidemiol. 2006;164(6):529–537.CrossRefGoogle ScholarPubMed
Boakye, D, Wyse, CA, Morales-Celis, CA, et al. Tobacco exposure and sleep disturbance in 498 208 UK Biobank participants. J Public Health (Oxf). 2018;40(3):517–526.CrossRefGoogle ScholarPubMed
Liao, Y, Xie, L, Chen, X, et al. Sleep quality in cigarette smokers and nonsmokers: findings from the general population in central China. BMC Public Health. 2019;19(1):808CrossRefGoogle ScholarPubMed
Peters, EN, Fucito, LM, Novosad, C, Toll, BA, O’Malley, SS. Effect of night smoking, sleep disturbance, and their co-occurrence on smoking outcomes. Psychol Addict Behav. 2011;25(2):312–319.CrossRefGoogle ScholarPubMed
Guzmán-Marín, R, Alam, MN, Mihailescu, S, Szymusiak, R, McGinty, D, Drucker-Colín, R. Subcutaneous administration of nicotine changes dorsal raphe serotonergic neurons discharge rate during REM sleep. Brain Res. 2001;888(2):321–325.CrossRefGoogle ScholarPubMed
Mihailescu, S, Guzmán-Marín, R, Drucker-Colín, R. Nicotine stimulation of dorsal raphe neurons: effects on laterodorsal and pedunculopontine neurons. Eur Neuropsychopharmacol. 2001;11(5):359–366.CrossRefGoogle ScholarPubMed
Saint-Mleux, B. Nicotinic enhancement of the noradrenergic inhibition of sleep-promoting neurons in the ventrolateral preoptic area. J Neurosci. 2004;24(1):63–67.CrossRefGoogle ScholarPubMed
Jaehne, A, Loessl, B, Bárkai, Z, Riemann, D, Hornyak, M. Effects of nicotine on sleep during consumption, withdrawal and replacement therapy. Sleep Med Rev. 2009;13(5):363–377.CrossRefGoogle ScholarPubMed
Patterson, F, Grandner, MA, Malone, SK, Rizzo, A, Davey, A, Edwards, DG. Sleep as a target for optimized response to smoking cessation treatment. Nicotine Tob Res. 2017;21(2):139–148.CrossRefGoogle Scholar
Ashare, RL, Lerman, C, Tyndale, RF, et al. Sleep disturbance during smoking cessation: withdrawal or side effect of treatment? J Smok Cessat. 2017;12(2):63–70.CrossRefGoogle ScholarPubMed
Cummings, KM, Giovino, G, Jaén, CR, Emrich, LJ. Reports of smoking withdrawal symptoms over a 21 day period of abstinence. Addict Behav. 1985;10(4):373–381.CrossRefGoogle Scholar
Sateia, MJ. International classification of sleep disorders-third edition: highlights and modifications. Chest. 2014;146(5):1387–1394. doi:10.1378/chest.14-0970.CrossRefGoogle ScholarPubMed
Salanti, G, Higgins, JPT, Ades, AE, Ioannidis, JPA. Evaluation of networks of randomized trials. Stat Methods Med Res. 2008;17(3):279–301.CrossRefGoogle ScholarPubMed
Riley, RD, Jackson, D, Salanti, G, et al. Multivariate and network meta-analysis of multiple outcomes and multiple treatments: rationale, concepts, and examples. BMJ. 2017;358:j3932.CrossRefGoogle Scholar
Salanti, G, Ades, AE, Ioannidis, JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163–171. doi:10.1016/j.jclinepi.2010.03.016.CrossRefGoogle ScholarPubMed
Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097.CrossRefGoogle ScholarPubMed
Medical Dictionary for Regulatory Activities Terminology (MedDRA) - Sleep disorders and disturbances - Classes | NCBO BioPortal [Internet]. https://bioportal.bioontology.org/ontologies/MEDDRA?p=classes&conceptid=http%3A%2F%2Fpurl.bioontology.org%2Fontology%2FMEDDRA%2F10040991. Accessed October 25, 2022.Google Scholar
Covidence Systematic Review Software, Veritas Health Innovation, Melbourne, Australia [Internet]. www.covidence.org.Google Scholar
Sterne, JAC, Savović, J, Page, MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.CrossRefGoogle ScholarPubMed
Owen, RK, Bradbury, N, Xin, Y, Cooper, N, Sutton, A. MetaInsight: an interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta. Res Syn Meth. 2019;10(4):569–581.CrossRefGoogle ScholarPubMed
Review Manager (RevMan) [Computer program]. Version 5.4. The Cochrane Collaboration, 2020.Google Scholar
Ahluwalia, JS, Harris, KJ, Catley, D, Okuyemi, KS, Mayo, MS. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. JAMA. 2002;288(4):468–474.CrossRefGoogle ScholarPubMed
Anthenelli, RM, Benowitz, NL, West, R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507–2520.CrossRefGoogle Scholar
Aubin, H-J, Bobak, A, Britton, JR, Oncken, C, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax. 2008;63(8):717–724.CrossRefGoogle ScholarPubMed
Aveyard, P, Lindson, N, Tearne, S, et al. Nicotine preloading for smoking cessation: the preloading RCT. Health Technol Assess. 2018;22(41):1–84.CrossRefGoogle ScholarPubMed
Baker, TB, Piper, ME, Stein, JH, et al. Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks: a randomized clinical trial. JAMA. 2016;315(4):371–379.CrossRefGoogle ScholarPubMed
Bolliger, CT, Issa, JS, Posadas-Valay, R, et al. Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2011;33(4):465–477.CrossRefGoogle ScholarPubMed
Cinciripini, PM, Robinson, JD, Karam-Hage, M. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry. 2013;70(5):33.CrossRefGoogle ScholarPubMed
Dalsgarð, ÓJ, Hansen, N-CG, Søes-Petersen, U, et al. A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees. Nicotine Tob Res. 2004;6(1):55–61.Google Scholar
Ebbert, JO, Croghan, IT, Hurt, RT, Schroeder, DR, Hays, JT. Varenicline for smoking cessation in light smokers. Nicotine Tob Res. 2016;18(10):2031–2035.CrossRefGoogle ScholarPubMed
Ebbert, JO, Croghan, IT, Schroeder, DR, Hurt, RD. A randomized phase II clinical trial of high-dose nicotine patch therapy for smokeless tobacco users. Nicotine Tob Res. 2013;15(12):2037–2044.CrossRefGoogle ScholarPubMed
Ebbert, JO, Hughes, JR, West, RJ, et al. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA. 2015;313(7):687–694.CrossRefGoogle ScholarPubMed
Fagerström, K, Gilljam, H, Metcalfe, M, Tonstad, S, Messig, M. Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial. BMJ. 2010;341:c6549.CrossRefGoogle ScholarPubMed
Fossati, R, Apolone, G, Negri, E, et al. A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. Arch Intern Med. 2007;167(16):1791–1797.CrossRefGoogle ScholarPubMed
Gonzales, D, Hajek, P, Pliamm, L, et al. Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2014;96(3):390–396. doi: 10.1038/clpt.2014.124.CrossRefGoogle ScholarPubMed
Gonzales, D, Rennard, SI, Nides, M, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47–55.CrossRefGoogle ScholarPubMed
Haggsträm, FM, Chatkin, JM, Sussenbach-Vaz, E, Cesari, DH, Fam, CF, Fritscher, CC. A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results. Pulm Pharmacol Ther. 2006;19(3):205–209.CrossRefGoogle ScholarPubMed
Holt, S, Timu-Parata, C, Ryder-Lewis, S, Weatherall, M, Beasley, R. Efficacy of bupropion in the indigenous Maori population in New Zealand. Thorax. 2005;60(2):120–123.CrossRefGoogle ScholarPubMed
Hurt, RD, Dale, LC, Fredrickson, PA, et al. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement. JAMA. 1994;271(8):595–600.CrossRefGoogle ScholarPubMed
Jorenby, DE, Hays, JT, Rigotti, NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):56–63.CrossRefGoogle ScholarPubMed
Jorenby, DE, Leischow, SJ, Nides, MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340(9):685–691.CrossRefGoogle ScholarPubMed
Lerman, C, Schnoll, RA, Hawk, LW, et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2015;3(2):131–138. doi:10.1016/S2213-2600(14)70294-2.CrossRefGoogle ScholarPubMed
McCarthy, DE, Piasecki, TM, Lawrence, DL, et al. A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling. Nicotine Tob Res. 2008;10(4):717–729.CrossRefGoogle ScholarPubMed
Niaura, R, Hays, JT, Jorenby, DE, et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr Med Res Opin. 2008;24(7):1931–1941.CrossRefGoogle ScholarPubMed
Nides, M. Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006;166(15):1561.CrossRefGoogle ScholarPubMed
Oncken, C, Gonzales, D, Nides, M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006;166(15):1571–1577.CrossRefGoogle ScholarPubMed
Rennard, S, Hughes, J, Cinciripini, PM, et al. A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. Nicotine Tob Res. 2012;14(3):343–350.CrossRefGoogle ScholarPubMed
Richmond, RL, Harris, K, de Almeida Neto, A. The transdermal nicotine patch: results of a randomised placebo-controlled trial. Med J Aust. 1994;161(2):130–135.CrossRefGoogle ScholarPubMed
Rigotti, NA, Pipe, AL, Benowitz, NL, Arteaga, C, Garza, D, Tonstad, S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease. Circulation. 2010;121(2):221–229.CrossRefGoogle ScholarPubMed
Rovina, N, Nikoloutsou, I, Katsani, G, et al. Effectiveness of pharmacotherapy and behavioral interventions for smoking cessation in actual clinical practice. Ther Adv Respir Dis. 2009;3(6):279–287.CrossRefGoogle ScholarPubMed
Sachs, DPL, Säwe, U, Leischow, SJ. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling. Arch Intern Med. 1993;153(16):1881–1890.CrossRefGoogle Scholar
Tonnesen, P, Mikkelsen, K. Varenicline to stop long-term nicotine replacement use: a double-blind, randomized, placebo-controlled trial. Nicotine Tob Res. 2013;15(2):419–427.CrossRefGoogle ScholarPubMed
Tonnesen, P, Tonstad, S, Hjalmarson, A, et al. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J Intern Med. 2003;254(2):184–192.CrossRefGoogle ScholarPubMed
Tsai, S-T, Cho, H-J, Cheng, H-S, et al. A randomized, placebo-controlled trial of varenicline, a selective α4β2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther. 2007;29(6):1027–1039.CrossRefGoogle ScholarPubMed
Tsukahara, H, Noda, K, Saku, K. A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers - efficacy, safety and withdrawal symptoms (the VN-SEESAW study). Circ J. 2010;74(4):771–778.CrossRefGoogle ScholarPubMed
Wang, C, Xiao, D, Chan, KPW, Pothirat, C, Garza, D, Davies, S. Varenicline for smoking cessation: a placebo-controlled, randomized study. Respirology. 2009;14(3):384–392.CrossRefGoogle ScholarPubMed
Williams, JM, Anthenelli, RM, Morris, CD, et al. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2012;73(5):16746.CrossRefGoogle ScholarPubMed
Zhang, H, Mansoursadeghi-Gilan, T, Hussain, S, et al. Evaluating the effectiveness of bupropion and varenicline for smoking cessation using an internet-based delivery system: a pragmatic randomized controlled trial (MATCH study). Drug Alcohol Depend. 2022;232:109312.CrossRefGoogle ScholarPubMed
Li, B-Z, Threapleton, DE, Wang, J-Y, et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ. 2015;351:h4052.CrossRefGoogle ScholarPubMed
Panikker, S, Lord, J, Jarman, JWE, et al. Outcomes and costs of left atrial appendage closure from randomized controlled trial and real-world experience relative to oral anticoagulation. Eur Heart J. 2016;37(46):3470–3482.CrossRefGoogle ScholarPubMed
Gourlay, SG, Forbes, A, Marriner, T, McNeil, JJ. Predictors and timing of adverse experiences during trandsdermal nicotine therapy. Drug Saf. 1999;20(6):545–555.CrossRefGoogle ScholarPubMed
Fredrickson, PA, Hurt, RD, Lee, GM, et al. High dose transdermal nicotine therapy for heavy smokers: safety, tolerability and measurement of nicotine and cotinine levels. Psychopharmacology (Berl). 1995;122(3):215–222.CrossRefGoogle ScholarPubMed
Wolter, TD, Hauri, PJ, Schroeder, DR, et al. Effects of 24-hr nicotine replacement on sleep and daytime activity during smoking cessation. Prev Med. 1996;25(5):601–610.CrossRefGoogle ScholarPubMed
Vazquez, J, Guzmán-Marín, R, Salín-Pascual, RJ, Drucker-Colín, R. Transdermal nicotine on sleep and PGO spikes. Brain Res. 1996;737(1–2):317–320.CrossRefGoogle ScholarPubMed
Page, F, Coleman, G, Conduit, R. The effect of transdermal nicotine patches on sleep and dreams. Physiol Behav. 2006;88(4‑5):425–432.CrossRefGoogle ScholarPubMed
Staner, L, Luthringer, R, Dupont, C, Aubin, H, Lagrue, G. Sleep effects of a 24-h versus a 16-h nicotine patch: a polysomnographic study during smoking cessation. Sleep Med. 2006;7(2):147–154.CrossRefGoogle ScholarPubMed
West, R, Baker, CL, Cappelleri, JC, Bushmakin, AG. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology. 2008;197(3):371–377.CrossRefGoogle ScholarPubMed
Pataka, A, Frantzidis, C, Nday, C, et al. Polysomnographic changes after varenicline administration for smoking cessation. ERJ Open Res. 2019;5(3):156.Google Scholar
Happe, S, Berger, K, On Behalf of the FAQT Study Investigators. The association of dopamine agonists with daytime sleepiness, sleep problems and quality of life in patients with Parkinson’s disease. J Neurol. 2001;248(12):1062–1067.CrossRefGoogle ScholarPubMed
Chakravorty, S, Chaudhary, NS, Brower, KJ. Alcohol dependence and its relationship with insomnia and other sleep disorders. Alcohol Clin Exp Res. 2016;40(11):2271–2282.CrossRefGoogle ScholarPubMed
Schierenbeck, T, Riemann, D, Berger, M, Hornyak, M. Effect of illicit recreational drugs upon sleep: cocaine, ecstasy and marijuana. Sleep Med Rev. 2008;12(5):381–389.CrossRefGoogle ScholarPubMed
Lewis, DA. Sleep in patients with asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2001;7(2):105–112.CrossRefGoogle ScholarPubMed
Etter, J-F, Burri, M, Stapleton, J. The impact of pharmaceutical company funding on results of randomised trials of nicotine replacement therapy for smoking cessation: a meta-analysis. Addiction. 2007;102(5):815–822.CrossRefGoogle ScholarPubMed
Hughes, JR, Hatsukami, D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986;43(3):289–294. doi:10.1001/archpsyc.1986.01800030107013.CrossRefGoogle ScholarPubMed
Morin, CM. Insomnia: Psychological assessment and management. Vol. xvii. New York, NY: Guilford Press; 1993:238.Google Scholar
Buysse, DJ, Reynolds, CF, Monk, TH, Berman, SR, Kupfer, DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213.CrossRefGoogle ScholarPubMed
Mills, EJ, Wu, P, Lockhart, I, Wilson, K, Ebbert, JO. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. Tob Induced Dis. 2010;8(1):8.CrossRefGoogle Scholar
Short, NA, Mathes, BM, Gibby, B, Oglesby, ME, Zvolensky, MJ, Schmidt, NB. Insomnia symptoms as a risk factor for cessation failure following smoking treatment. Addict Res Theory. 2017;25(1):17–23.CrossRefGoogle ScholarPubMed
Dorner, TE, Tröstl, A, Womastek, I, Groman, E. Predictors of short-term success in smoking cessation in relation to attendance at a smoking cessation program. Nicotine Tob Res. 2011;13(11):1068–1075.CrossRefGoogle Scholar
Peltier, MR, Lee, J, Ma, P, Businelle, MS, Kendzor, DE. The influence of sleep quality on smoking cessation in socioeconomically disadvantaged adults. Addict Behav. 2017;66:7–12.CrossRefGoogle ScholarPubMed
Okun, ML, Levine, MD, Patricia, H, Perkins, KA, Marcus, MD. Subjective sleep disturbance during a smoking cessation program: associations with relapse. Addict Behav. 2011;36:861–864.CrossRefGoogle ScholarPubMed
Vanderkam et al. supplementary material
Vanderkam et al. supplementary material
File
55.2 KB